Amyris Biotech Files for $100 Million IPO

Amyris Biotechnologies Inc., an Emeryville, Calif.-based synthetic biology company that developers renewable hydrocarbon biofuels, has filed for a $100 million IPO. It plans to trade under ticker symbol AMRS, with Goldman Sachs, J.P. Morgan and Morgan Stanley serving as co-lead underwriters.

The company reports $64 million in 2009 revenue, compared to $14 million in 2008.

Amyris has raised over $240 million in VC funding, from Kleiner Perkins (15.4% pre-IPO stake), Kohsla Ventures (15.4%), TPG Biotech (12.1%), Advanced Equities (6.7%), Temasek Holdings, DAG Ventures, Votorantim Novos Negocios, Grupo Cornélio Brennand, Naxos UK, The Westly Group and Stratus Group.

Leave a Reply

PE HUB Community

Join the 12522 members of PE HUB to make connections, share your opinion, and follow your favorite authors.

Join the Community

Look Who’s Tweeting

PE HUB News Briefs

RSS Feed Widget